Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:49 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Terminated Not applicable Interventional Results available

Arthrex Eclipse™ Shoulder Prosthesis

NCT01790113
View directory record Official record
Conditions
Osteoarthritis
Interventions
Univers™, Eclipse™ Total Shoulder Replacement
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Sun City, Arizona • Redwood City, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional Results available

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

NCT03999684
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Tretinoin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Nov 2, 2026, 10:49 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants

NCT01809431
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Nov 2, 2026, 10:49 AM EST
Not listed Phase 2 Interventional

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

NCT04822961
View directory record Official record
Conditions
mCRPC
Interventions
Placebo, Senaparib
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Nov 2, 2026, 10:49 AM EST
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Carlsbad, California • Fort Collins, Colorado • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

NCT00359944
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-3933, Sugar Pill
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Nov 2, 2026, 10:49 AM EST
Not yet recruiting Not applicable Interventional

HOPE Intervention for Fitness

NCT07114822
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Harnessing Online Peer Education
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

NCT01230346
View directory record Official record
Conditions
No Evidence of Disease, BRCA1 Syndrome, BRCA2 Syndrome, Hereditary Female Breast Carcinoma, Hereditary Ovarian Carcinoma
Interventions
questionnaire administration, survey administration, counseling intervention, educational intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
493 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Terminated Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254
View directory record Official record
Conditions
Herpes Simplex
Interventions
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional Results available

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

NCT00824005
View directory record Official record
Conditions
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Nov 2, 2026, 10:49 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

NCT02339870
View directory record Official record
Conditions
Caregiver
Interventions
Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional Results available

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT01896531
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

NCT00286429
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and insulin, Insulin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 2, 2026, 10:49 AM EST
Terminated Phase 3 Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

NCT00306137
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Nov 2, 2026, 10:49 AM EST
Recruiting Not applicable Interventional

NT-II™ Collagen for Joint Discomfort and Function

NCT07119645
View directory record Official record
Conditions
Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
Interventions
NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
20 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 10:49 AM EST
Completed Not applicable Interventional

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

NCT01013337
View directory record Official record
Conditions
Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, sham intervention
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Nov 2, 2026, 10:49 AM EST
Terminated Phase 2 Interventional Results available

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

NCT01858753
View directory record Official record
Conditions
Restrictive Burn Scars
Interventions
Autologous fibroblasts, placebo sterile saline
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 3 Interventional

Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer

NCT00090337
View directory record Official record
Conditions
Head and Neck Cancer, Pain
Interventions
acupuncture therapy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Nov 2, 2026, 10:49 AM EST
Not listed Phase 2 Interventional

Phase II Proof of Concept Study in Uncomplicated UTI

NCT03129295
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
MPC-SHRC, Placebo Oral Tablet
Drug
Lead sponsor
Mission Pharmacal
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Jeffersonville, Indiana • Kalamazoo, Michigan • Lawrenceville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Nov 2, 2026, 10:49 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 2, 2026, 10:49 AM EST